Categories Earnings, Health Care

Aphria stock sinks on disappointing Q3 bottom-line

Shares of Canadian cannabis company Aphria Inc (NYSE:APHA) fell 8.9% during the pre-market hours on Monday after it reported a third-quarter adjusted loss of $0.15 (C$0.20) per share, much wider than the loss of 4 cents per share expected by the street.

On a reported basis, the weed giant swung to a loss of $0.32 (C$0.43) per share, from a profit of $0.06 (C$0.08) per share in the same quarter last year.

Net revenues, meanwhile, jumped more than seven times to $55.2 (C$73.6) million, driven by CC Pharma and ABP. Analysts were expecting $41.1 million.

aphria earnings and revenue trend


During the quarter, the company saw a decline in cannabis revenue as well as kilograms sold, primarily due to operational transition and temporary distribution challenges, the company said.

The Aphria Board also announced the appointed two new independent directors, effective today. Walter Robb and David Hopkinson will fill two of the three current director vacancies.

In a separate release earlier today, the Ontario-based company said it has entered into a series of transactions that will accelerate the expiry date for the take-over bid by Green Growth Brands to April 25, 2019, and will terminate the arrangements with GA Opportunities Corp. for $89 million. In December, Aphria rejected Green Growth Brands’ $2.1 billion (C$2.8 billion) buyout offer stating that the latter’s proposal undervalued the former.

Late last year, Aphria shares got hammered following a report from Hindenburg Research, which stated that Aphria’s LATAM acquisition is worthless and accused that a network of insiders of Aphria diverted funds from shareholders and put them into their own pockets.


The Canadian government has committed to regulating the sale of cannabis-infused products in 2019. Based on customer behavior and product preferences demonstrated in other existing legal markets, the Ontario, Canada-based cannabis firm believes cannabis-infused products could represent more than 50% of the total cannabis market upon becoming federally legal in Canada.

Earlier this month, Aphria’s German subsidiary received a license for the domestic cultivation of medical cannabis. Cannabis companies have started focusing on the beauty area. On April 1, Aphria launched CBD-based cosmetics product in the German market.

The stock, which started trading on the NYSE on November 2, 2018, has gained 81% since the beginning of this year.


Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!


Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

One thought on “Aphria stock sinks on disappointing Q3 bottom-line

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment

Viewing Highlight